Experts Provide Much-Needed Policy Analysis for Clinical Integration of Next Generation Sequencing
By Glenna Picton,
Baylor College of Medicine News
| 09. 22. 2014
Untitled Document
As genetic sequencing technologies continue to evolve rapidly, becoming part of clinical care, there is a critical need to establish appropriate policies and regulatory frameworks to address potential challenges, legal and ethical experts have said. A special policy issue of the Journal of Law, Medicine & Ethics published online today and edited by experts with the Center for Medical Ethics and Health Policy at Baylor College of Medicine gives policy makers the tools to jumpstart this process.
Experts with the Center for Medical Ethics and Health Policy at Baylor were tapped to serve as editors of this special issue of the journal, which addressed a variety of topics including U.S. Food and Drug Administration regulation, reimbursement, intellectual property issues, and proprietary databases. They did so with the help of a $1.6 million National Human Genome Research Institute grant to Dr. Amy McGuire, director of the Center and a leading expert on legal and ethical issues in genetics. The grant allowed experts to study how the evolution of the next generation sequencing industry impacts these major policy areas.
Next...
Related Articles
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...